Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | SDHB | P21912 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2859011 | 0.85 | ALDH1A1 (0.43) | RAB9AKMT2AALDH1A1CES2CES1 | |
| SCHEMBL2867866 | 0.85 | ALDH1A1 (0.43) | RAB9AKMT2AALDH1A1CES2CES1 | |
| SCHEMBL2859012 | 0.85 | ALDH1A1 (0.43) | RAB9AKMT2AALDH1A1CES2CES1 | |
| SCHEMBL11830228 | 0.81 | CYP4F2 (0.40) | KMT2AALDH1A1CYP4F2CYP4A11LMNA | |
| SCHEMBL11095339 | 0.79 | KMT2A (0.41) | KMT2AALDH1A1CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL1946731 | 0.79 | L3MBTL1 (0.41) | NPC1RAB9AKMT2AALDH1A1CES2 | |
| SCHEMBL12546521 | 0.79 | L3MBTL1 (0.41) | NPC1RAB9AKMT2AALDH1A1CES2 | |
| SCHEMBL5915071 | 0.78 | NPC1 (0.39) | NPC1RAB9AKMT2AALDH1A1CES2 | |
| SCHEMBL5915046 | 0.78 | NPC1 (0.39) | NPC1RAB9AKMT2AALDH1A1CES2 | |
| SCHEMBL6382070 | 0.78 | NPC1 (0.39) | NPC1RAB9AKMT2AALDH1A1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034961-B2 | Reduction of 4-aryl-4-ketobutanoic acid derivatives utilizing ruthenium containing catalysts | LANXESS DEUTSCHLAND GMBH (US) | 2011-10-11 | — | — | US | disclosed |
| US-20080103316-A1 | Process for stereoselectively reducing 4-ARYL-4-oxobutanoic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-05-01 | — | — | US | disclosed |
| US-7329766-B2 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20050245760-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-11-03 | — | — | US | disclosed |
| US-6921822-B2 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-07-26 | — | — | US | disclosed |
| US-20040030181-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | disclosed |
| EP-1369410-A1 | Process for the stereoselective reduction of derivatives of 4-aryl-4-oxobutyric acid | BAYER AG (DE) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103316-A1 | Process for stereoselectively reducing 4-ARYL-4-oxobutanoic acid derivatives | HPD, GRHPR, CYP4B1 | NPC1 3145/4885RAB9A 3582/4885KMT2A 692/4885 |
| US-20040030181-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | HPD, GRHPR, CYP4B1 | NPC1 3145/4885RAB9A 3582/4885KMT2A 692/4885 |
| US-20050245760-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | HPD, GRHPR, CYP4B1 | NPC1 3145/4885RAB9A 3582/4885KMT2A 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.